Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Arcutis Biotherapeutics (NASDAQ: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, June 10, 2025, at 4:00 pm EDT. The event will be accessible via webcast in the "Events" section of Arcutis' website, with the replay remaining available for 180 days after the conference.
Arcutis Biotherapeutics (NASDAQ: ARQT), un'azienda biofarmaceutica in fase commerciale specializzata in innovazioni immuno-dermatologiche, ha annunciato la sua partecipazione alla 46ª Conferenza Globale Annuale sulla Sanità di Goldman Sachs. Il management dell'azienda prenderà parte a una discussione informale il martedì 10 giugno 2025, alle 16:00 EDT. L'evento sarà accessibile via webcast nella sezione "Eventi" del sito web di Arcutis, con la replica disponibile per 180 giorni dopo la conferenza.
Arcutis Biotherapeutics (NASDAQ: ARQT), una empresa biofarmacéutica en etapa comercial especializada en innovaciones en inmunodermatología, ha anunciado su participación en la 46ª Conferencia Global Anual de Salud de Goldman Sachs. La dirección de la compañía participará en una charla informal el martes 10 de junio de 2025 a las 4:00 pm EDT. El evento estará disponible vía webcast en la sección "Eventos" del sitio web de Arcutis, y la repetición estará accesible durante 180 días después de la conferencia.
Arcutis Biotherapeutics (NASDAQ: ARQT)는 면역 피부학 혁신을 전문으로 하는 상업 단계의 생명공학 제약회사로, 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2025년 6월 10일 화요일 오후 4시(동부 표준시)에 파이어사이드 채팅에 참여할 예정입니다. 이 행사는 Arcutis 웹사이트의 "이벤트" 섹션을 통해 웹캐스트로 시청할 수 있으며, 컨퍼런스 후 180일 동안 다시보기 서비스를 제공합니다.
Arcutis Biotherapeutics (NASDAQ : ARQT), une entreprise biopharmaceutique en phase commerciale spécialisée dans les innovations en immunodermatologie, a annoncé sa participation à la 46e conférence mondiale annuelle sur la santé de Goldman Sachs. La direction de la société participera à une discussion informelle le mardi 10 juin 2025 à 16h00 EDT. L'événement sera accessible en webcast dans la rubrique « Événements » du site web d'Arcutis, avec une rediffusion disponible pendant 180 jours après la conférence.
Arcutis Biotherapeutics (NASDAQ: ARQT), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Innovationen in der Immun-Dermatologie spezialisiert hat, hat seine Teilnahme an der 46. Goldman Sachs Global Healthcare Konferenz angekündigt. Das Management des Unternehmens wird am Dienstag, den 10. Juni 2025, um 16:00 Uhr EDT an einem Fireside-Chat teilnehmen. Die Veranstaltung wird per Webcast im Bereich "Events" auf der Webseite von Arcutis zugänglich sein, die Aufzeichnung ist 180 Tage nach der Konferenz verfügbar.
- None.
- None.
WESTLAKE VILLAGE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, taking place June 9-11, 2025.
Details for the company’s participation are as follows:
Fireside Chat Date: Tuesday, June 10, 2025
Fireside Chat Time: 4:00 pm EDT
The webcast for this conference may be accessed at the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline with multiple follow-on clinical programs for a range of inflammatory dermatological conditions including atopic dermatitis and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Latha Vairavan, Chief Financial Officer
ir@arcutis.com
FAQ
When is Arcutis (ARQT) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I watch Arcutis' (ARQT) presentation at the Goldman Sachs Healthcare Conference?
What type of company is Arcutis Biotherapeutics (ARQT)?
How long will the replay of Arcutis' (ARQT) Goldman Sachs conference presentation be available?
